CELC - Celcuity Inc.
IEX Last Trade
10.85
0.085 0.783%
Share volume: 428,363
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.38%
PREVIOUS CLOSE
CHG
CHG%
$10.76
-1.07
-0.09%
Fundamental analysis
8%
Profitability
8%
Dept financing
8%
Liquidity
47%
Performance
0%
Performance
5 Days
-8.98%
1 Month
-13.55%
3 Months
-28.43%
6 Months
-42.26%
1 Year
-25.17%
2 Year
-6.87%
Key data
Stock price
$10.85
DAY RANGE
$10.35 - $11.79
52 WEEK RANGE
$11.79 - $22.19
52 WEEK CHANGE
-$25.17
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Brian F. Sullivan
Region: US
Website: celcuity.com
Employees: 40
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: celcuity.com
Employees: 40
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Celcuity Inc. focuses on the development of molecularly targeted therapies for cancer patients in the United States. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3k signaling activity in breast and ovarian tumor cells.
Recent news